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The association of endometrial thickness with the risk of developing endometrial cancer (EC) within 2 years was investigated in a
consecutive cohort of 1205 breast cancer patients under tamoxifen treatment, undergoing transvaginal ultrasonography (TVUS) for
follow-up purpose (asymptomatic, 1068) or for abnormal uterine bleeding (AUB, 137). Linkage with tumour registry allowed for the
follow-up of 3184.3 person-years. According to underlying incidence, 1.85 EC cases were expected in the study cohort while 12
were observed (observed/expected ratio¼6.49, 95% CI 3.35–11.33; asymptomatic¼4.09, 95% CI 1.65–8.43,
symptomatic¼35.71, 95% CI 11.59–83.34). No EC was observed with thickness (half layer) o3mm. Raising this threshold
increased specificity with a substantial loss of sensitivity (X3, X4, X6, X9mm; spec.¼25.8, 44.5, 76.1, 91.5%, sens.¼100, 91.6,
75.0, 66.6%). The presence of AUB was rather specific (88.94%) but poorly sensitive (41.67%). A combination of AUB presence/
absence and thickness allowed the best accuracy (AUB + thickness X3, X4o rX5; sens.¼100, 81.6 or 91.6%; spec.¼22.8, 40.4, or
56.7%). Breast cancer patients under tamoxifen might be selected for further invasive assessment on the basis of AUB and
endometrial thickness assessed at TVUS.
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Several studies report an increase of endometrial cancer (EC) risk
in breast cancer patients after long-term tamoxifen treatment
(Fornander et al, 1989; Fisher et al, 1994, Cecchini et al, 1998);
such a finding is only partially explained by the association
between EC and breast cancer (Teppo et al, 1985; Crocetti et al,
2001), and tamoxifen is most likely responsible for the large part of
such increased risk. For this reason, special surveillance for EC has
been suggested in breast cancer patients under adjuvant tamoxifen
treatment (Jordan and Morrow, 1994; Neven et al, 1994) and
periodic examination by transvaginal ultrasonography (TVUS) is
commonly performed (Oladipo, 1993; Kedar et al, 1994). Increased
endometrial thickness measured at TVUS has been reported as an
indicator of endometrial proliferation and EC risk (Karlsson et al,
1995; Weber et al, 1997) and has been suggested as a criterion to
prompt invasive diagnostic assessment (hysteroscopy, dilatation
and curettage) in postmenopausal asymptomatic or symptomatic
(AUB¼abnormal uterine bleeding) women (Goldstein et al, 1990;
Osmers et al. 1990; Cecchini et al, 1996; Langer et al, 1997; Smith-
Bindman et al, 1998).
At the Centro per lo Studio e la Prevenzione Oncologica (CSPO)
of Florence, a large number of breast cancer patients under
tamoxifen treatment are currently followed up and periodic TVUS
examination has been commonly performed since many years
(Cecchini et al, 1998). A retrospective study has been designed
with the purpose of assessing whether endometrial thickening is
associated with increased risk of EC and may be used as an
indicator for invasive assessment.
MATERIALS AND METHODS
Subjects eligible for the study were postmenopausal (amenorrhaea
since 1 year at least) breast cancer patients under tamoxifen
treatment since at least 1 year, referring to CSPO for TVUS as a
periodic control (asymptomatic) or because of abnormal uterine
bleeding (AUB, symptomatic) from November 1993 to December
1999. No standard interval following onset of tamoxifen therapy
was adopted, and reliable data on total duration of treatment were
not available. TVUS was carried out with an SS250 Toshiba
sonograph using a dedicated transvaginal convex 7MHz transdu-
cer. Data available for each case were: name, birth date, TVUS date,
symptoms (none, AUB), endometrial thickness in millimetres
(single layer, determined on the longitudinal scan at the point of
maximum thickness), diagnostic report (negative, benign, suspi-
cious for endometrial cancer).
Eligible cases were linked with the Tuscany Tumour Registry
database (linkage by name and date of birth) to identify subjects
with EC (ICDO¼1820) incident after TVUS date until December
1999. Patterns (median time from TVUS) of EC occurrence in
symptomatic and asymptomatic cases were compared. Statistical
analysis was based on Student’s t-test to compare means of
unmatched samples and Pearson w
2 to compare medians.
Standardised (European population) incidence rates were calcu-
lated according to person-years in the overall series and according
to symptomatic status. The number of EC cases observed in the
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lstudy cohort was compared to that expected according to cancer
registry age-adjusted incidence rates in the general population, and
observed/expected (O/E) ratio and its 95% confidence interval
(95% CI) were calculated. Sensitivity, specificity and negative/
positive predictive values for EC were determined for different
cutoffs of endometrial thickness. Receiver operating characteristics
(ROC) curve analysis were also applied for different endometrial
thickness cutoffs. We evaluated the possible clinical use of
endometrial thickness measured at TVUS as a choice criterion
between surveillance and immediate invasive assessment (hystero-
scopy, dilatation and curettage) for asymptomatic and sympto-
matic subjects.
RESULTS
The study cohort consists of 1205 eligible subjects (age range 37–
92 years, median 64) of whom 1.068 were asymptomatic and 137
were symptomatic (no age difference was evident according to age:
data not reported). Subjects had been followed up for a total of
3184.3 person-years (asymptomatic¼2949.7; symptomatic¼
244.6). Linkage with tumour registry files identified incident EC
in 12 subjects (asymptomatic¼7, symptomatic¼5). The main
features of these cases are shown in Table 1. Endometrial cancer
was diagnosed in the average 6.57 months after TVUS (range 0.10–
15.54 months, s.d. 5.34): the interval between TVUS and EC
diagnosis was significantly shorter for symptomatic (average 2.84
months, range 0.95–4.44 months, s.d. 1.37) as compared to
asymptomatic cases (average 9.24 months, range 0.10–15.54
months, s.d. 5.57, P¼0.03). Histological grading was available in
11 cases (G1¼4, G2¼5, G3¼2). Myometrial invasion was
observed in 10 of 12 cases. High-grade (G3) and extensive
(450%) myometrial invasion was observed in cases with AUB.
The standardised EC incidence rate was 15.29 1000
(symptomatic¼84.08, asymptomatic¼5.50). Based on incidence
rates in the general population (cancer registry) and person-years,
1.85 EC cases were expected in the study cohort while 12 were
observed with an O/E ratio of 6.49 (95% CI 3.35–11.33).
Corresponding values for asymptomatic or symptomatic cases
were 4.09 (95% CI 1.65–8.43) and 35.71 (95% CI 11.59–83.34),
respectively.
Table 2 shows the distribution of asymptomatic/symptomatic,
cancer/noncancer cases by endometrial thickness. Sensitivity and
specificity for EC occurring within 2 years from TVUS calculated
for different cutoffs of endometrial thickness are shown in Table 3.
A cutoff X3mm was associated with 100% sensitivity but with a
relatively low specificity (25.82%). To increase specificity to 440
(cutoff X4mm), 475 (X6mm) or 490% (X9mm); a substantial
loss of sensitivity was evident (83.33, 75.00 or 66.67%, respec-
tively). At ROC analysis, the area under the curve was 0.8217
(s.e.¼0.0573, 95% CI¼0.70930–0.93411). The ROC curve is
shown in Figure 1.
Table 3 shows the number of EC delayed diagnoses and of
unnecessary assessments that would occur by using different
indicators to prompt immediate invasive diagnostic assessment:
(a) different thickness cutoff, (b) presence of AUB, (c) suspicious
TVUS findings or (d) different combinations of indicators (a+b,
a+c). Endometrial thickness X3mm allowed 100% sensitivity, but
would spare only 25.8% of invasive assessments. A higher
proportion of invasive assessments was spared (44.5, 62.1, 76.1,
82.5%) by raising the thickness cutoff (X4, X5 X6, X7mm),
although with a substantial loss in sensitivity. The presence of AUB
was a rather specific (88.9%) but poorly sensitive indicator
(41.6%), whereas the reverse was true for suspicious TVUS (757
negative or benign cases, 448 suspicious: sensitivity 81.8,
specificity 63.2%). The combination of the presence of AUB and
of a thickness X4mm allowed for a very favourable balance
(sensitivity 91.6%, specificity 40.4%): raising the thickness cutoff
to X5mm or X6mm further reduced unnecessary assessments
(56.7 or 69.9%) with no loss in sensitivity.
Multivariate analysis of the association of age (continuous
variable), endometrial thickness (continuous variable) and symp-
toms (present/absent) to EC occurrence within 2 years after TVUS
is shown in Table 4. Age showed no significant association with EC
risk. The presence of symptoms was associated with a significant
independent increase of risk (6.23:1) as compared to asympto-
matic status. Thickness showed also a significant association with
EC risk increasing by 16% for each extra millimetre of thickness.
When entered in the model, TVUS diagnosis (negative/benign vs
suspicious of cancer) showed a nearly significant association with
EC (RR¼4.33, 95% CI 0.76–24.45), and symptoms remained the
most significantly associated variable (RR¼4.51; 95% CI 1.25–
15.01) whereas thickness reduced its association, with risk
increasing by 8% per millimetre increase, but at a nonsignificant
level.
DISCUSSION
The present study is based on a relatively large sample of breast
cancer patients under tamoxifen treatment, followed up by cancer
registry, and allows reliable considerations on the possible role of
TVUS-assessed endometrial thickness as an indicator for invasive
assessment aimed at early detection of EC.
This study confirms an increased risk of EC in subjects
undergoing tamoxifen treatment, already reported in the literature
Table 1 Age and symptoms at TVUS, TVUS report, endometrial thickness (half layer) and TVUS endometrial cancer diagnosis interval in 12 EC cases
observed in the present study
Case Age Symptoms TVUS report
Thickness
(mm)
TVUS EC diagnosis
interval
Histological
grading
% Myometrial
invasion
1 64 AUB Suspicious 9 13.80 (months) Unknown 50%
2 59 AUB Suspicious 10 0.10 G1 Intramucous
3 66 AUB Suspicious 10 8.31 G2 20%
4 55 None Suspicious 9 4.44 G1 Intramucous
5 71 AUB Suspicious 9 3.84 G2 40%
6 74 AUB Negative 3 15.54 G1 5%
7 57 None Suspicious 5 3.61 G2 45%
8 62 None Suspicious 10 2.00 G2 40%
9 50 None Negative 4 0.95 G2 30%
10 67 AUB Suspicious 6 10.68 G3 40%
11 75 None Suspicious 9 3.19 G1 20%
12 75 AUB Suspicious 10 12.42 G3 60%
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l(Fornander et al, 1989; Fisher et al, 1994), and in a previous study
on a smaller cohort (Cecchini et al, 1998). If a selection bias is
most likely in subjects self-referring for AUB, this is probably not
true for asymptomatic subjects who were referred for TVUS as a
routine follow-up procedure: although cases with AUB, which
account for the majority of incident EC, were excluded from this
subgroup, it still showed a significantly increased EC relative risk,
exceeding four-folds that of the general population.
Endometrial thickness assessed at TVUS is commonly used as
an indicator of EC risk (Karlsson et al, 1995; Weber et al, 1997).
The decision of measuring single endometrial layer maximum
thickness (rather than endometrium as a whole) was aimed at a
better definition of cases with focal thickening, involving one
single layer, which might be missed or underestimated at whole
endometrium measurement; however, these cases are relatively
rare, and in the large majority endometrial thickening is
symmetrical and single-layer maximum thickness equals half the
whole endometrium thickness.
The main problem with endometrial thickness in patients under
tamoxifen treatment is that tamoxifen has been shown to induce
subendometrial changes that simulate endometrial hyperplasia at
TVUS (Goldstein, 1994), while atrophia is often the only finding at
Table 2 Distribution of the study cohort according to presence of EC cancer, symptoms and endometrial
thickness (half layer)
Total cases Symptomatic Asymptomatic
Thickness (mm) Cancer Noncancer Cancer Noncancer Cancer Noncancer
0 0 14 0 1 0 13
1 0 94 0 17 0 77
2 0 200 0 17 0 183
3 1 223 0 14 1 209
4 1 210 1 15 0 195
5 1 168 1 10 0 158
6 1 76 0 12 1 64
7 0 62 0 6 0 56
8 0 45 0 12 0 33
9 4 23 2 5 2 18
10 4 31 1 7 3 24
1 1 07 05 0 2
1 2 06 01 0 5
1 3 04 03 0 1
1 4 03 01 0 2
1 5 08 01 0 7
1 6 05 02 0 3
1 7 03 01 0 2
1 8 01 00 0 1
1 9 02 02 0 0
2 0 08 00 0 8
Total 12 1193 5 132 7 1061
Table 3 Number of EC delayed diagnoses and of unnecessary assessments, sensitivity, specificity and
predictive values (PV) for different cutoffs of endometrial thickness (half layer) and for different protocols
prompting immediate invasive diagnostic assessment for EC
Invasive
assessment if:
EC delayed
diagnoses
Unnecessary
assessments Sens % Spec % PPV % NPV %
Thickness X2 0 1085 100 9.05 1.09 100
Thickness X3 0 885 100 25.82 1.34 100
Thickness X4 1 662 91.67 44.51 1.66 99.81
Thickness X5 2 452 83.33 62.11 2.16 99.63
Thickness X6 3 284 75.00 76.19 3.07 99.67
Thickness X7 4 208 66.67 82.56 3.70 99.60
Thickness X8 4 146 66.67 87.76 5.19 99.62
Thickness X9 4 101 66.67 91.53 7.34 99.64
AUB 7 132 41.67 88.94 3.65 99.34
Suspicious TVUS 2 438 83.33 63.29 2.23 99.74
AUB/thickness X3 0 920 100 22.88 1.29 100
AUB/thickness X4 1 711 91.67 40.40 1.52 99.79
AUB/thickness X5 1 516 91.67 56.75 2.09 99.85
AUB/thickness X6 1 358 91.67 69.99 2.02 99.88
AUB/thickness X7 2 294 83.33 75.36 3.29 99.78
AUB/thickness X8 2 238 83.33 80.05 4.03 99.79
AUB/thickness X9 2 205 83.33 82.82 4.65 99.80
AUB/suspicious TVUS 1 476 91.67 60.10 2.26 99.86
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endometrial thickness as the only indicator for invasive assessment
implies a large number of false positives, even at TVUS diagnosis,
and of unnecessary assessments (Osmers et al, 1990; Ciatto et al,
1995).
In the present study only a cutoff of X3mm would be
totally safe, granting for no missed cancer, but it would allow
a limited (25.8%) reduction of unnecessary invasive assess-
ments. Attempts to increase specificity and the proportion of
spared unnecessary assessments by raising the X3mm cutoff led
to a decrease of sensitivity, which became rapidly clinically
unacceptable.
Combination with other clinical indicators such as the presence
of AUB allowed to increase the thickness cutoff while maintaining
good levels of sensitivity with a reduction of unnecessary
assessment which is of clinical interest (AUB + thickness X3,
X4o rX5; sens.¼100, 91.6 or 91.6%; spec.¼22.8, 40.4 or 56.7%).
AUB is often considered sufficient to indicate invasive assess-
ment in these patients, or even in the general population (Karlsson
et al, 1995; Weber et al, 1997), but AUB is often spurious and
poorly predictive of EC (the positive predictive value was only
3.65% in the present series). Abnormal uterine bleeding might not
prompt invasive assessment when associated with low endometrial
thickness: in the present study, 49 of 137 (35.77%) subjects with
AUB had a thickness p3mm and showed no cancer at follow-up.
These subjects might be better put under watchful waiting, in that
spurious AUB is often anecdotal, whereas EC-related bleeding
tends to persist. Our findings suggest adopting a cutoff that is
substantially higher, and much rewarding in terms of spared
unnecessary invasive assessments, as compared to a large study
suggesting a cutoff of 2.5mm (Smith-Bindman et al, 1998).
Periodic follow-up of breast cancer patients under tamoxifen
treatment aimed at early detection of EC is a common practice,
justified by the evidence of tamoxifen-induced increased risk of EC
in these subjects. Although early detection of EC is possible by
adopting intensive surveillance policies, there is no evidence
supporting that early detection and treatment will improve EC
prognosis, which is relatively good even in symptomatic cases,
showing a very high cure rate. Although the difference is not
statistically significant, it is worth noting that adverse EC
prognostic indicators such as high histological grade (G3) and
extensive (450%) myometrial invasion were observed only in
subjects with AUB at diagnosis: this might suggest delayed
detection being associated with AUB, but this finding is based
on a few cases and needs to be confirmed on a larger EC series. On
the contrary, awareness of increased EC risk prompting special
surveillance will cause further anxiety in these cancer patients, and
false-positive findings, which may be relatively common, will cause
unnecessary invasive assessments. A good specificity of the
adopted surveillance protocol must thus be granted, and TVUS-
assessed endometrial thickness seems to be a good indicator to be
used, together with TVUS diagnostic findings and the presence of
AUB, as a determinant for invasive assessment.
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Figure 1 ROC curve of sensitivity and specificity for EC based on
different cutoff levels (1–20mm) of endometrial thickness (half thickness).
Table 4 Multivariate analysis of the association (RR=relative risk) of age
(continuous variable), endometrial thickness (continuous variable) and
symptoms (present/absent) to EC occurrence within 2 years from TVUS
Variable RR 95% CI s.e. P-value
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Symptoms 6.23 1.91–20.30 3.75 0.002
Surveillance for tamoxifen-induced endometrial cancer
S Ciatto et al
1178
British Journal of Cancer (2003) 88(8), 1175–1179 & 2003 Cancer Research UK
C
l
i
n
i
c
a
lOsmers R, Volksen M, Schnauer A (1990). Vaginosonography for early
detection of endometrial carcinoma? Lancet 335: 1569–1571
Smith-Bindman R, Kerlikowske K, Feldstein VA (1998) Endovaginal
ultrasound to exclude endometrial cancer and other endometriale
abnormalities. JAMA 280: 1510–1517
Teppo I, Pukkala E, Saxen E (1985) Multiple cancer. An epidemiologic
exercise in Finland. J Natl Cancer Inst 75: 207–217
Weber A, Belinson JL, Bradley LD, Piedmonte MR (1997) Vaginal
ultrasonography versus endometrial biopsy in women with postmeno-
pausal bleeding. Am J Obstet Gynecol 177: 924–929
Surveillance for tamoxifen-induced endometrial cancer
S Ciatto et al
1179
British Journal of Cancer (2003) 88(8), 1175–1179 & 2003 Cancer Research UK
C
l
i
n
i
c
a
l